These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28674251)

  • 21. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
    Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
    Meadowcroft AM; Williamson KM; Patterson JH; Hinderliter AL; Pieper JA
    J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
    Transon C; Leemann T; Vogt N; Dayer P
    Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
    Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
    Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
    Huth F; Gardin A; Umehara K; He H
    Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.
    Li DQ; Kim R; McArthur E; Fleet JL; Bailey DG; Juurlink D; Shariff SZ; Gomes T; Mamdani M; Gandhi S; Dixon S; Garg AX
    CMAJ; 2015 Feb; 187(3):174-180. PubMed ID: 25534598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
    Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
    Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.
    Andersson TB; Bredberg E; Ericsson H; Sjöberg H
    Drug Metab Dispos; 2004 Jul; 32(7):715-21. PubMed ID: 15205386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.
    Sane RS; Ramsden D; Sabo JP; Cooper C; Rowland L; Ting N; Whitcher-Johnstone A; Tweedie DJ
    Drug Metab Dispos; 2016 Mar; 44(3):466-75. PubMed ID: 26684498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3).
    Shiozawa A; Yamaori S; Kamijo S; Ohmori S
    Drug Metab Pharmacokinet; 2021 Feb; 36():100364. PubMed ID: 33341662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.
    Miroševic Skvrce N; Božina N; Zibar L; Barišic I; Pejnovic L; Macolic Šarinic V
    Pharmacogenomics; 2013 Sep; 14(12):1419-31. PubMed ID: 24024895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
    De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
    Qiang F; Lee BJ; Lee W; Han HK
    Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys.
    Hartman HA; Myers LA; Evans M; Robison RL; Engstrom RG; Tse FL
    Fundam Appl Toxicol; 1996 Jan; 29(1):48-62. PubMed ID: 8838639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
    Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
    J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.